Summary
From July 1984 to November 1987, 89 patients with recurrent measurable squamous-cell cancer of the uterine cervix were randomized in a single institution to receive treatment with either carboplatin (CBDCA) or iproplatin (CHIP). Objective response rates were similar: 2 complete regressions (CRs) and 10 partial regressions (PRs) were recorded both in the 46 evaluable patients treated with CBDCA (response rate, 26.1%; 95% confidence interval, 15–41%) and in the 40 evaluable patients treated with CHIP (response rate, 30%; 95% confidence interval, 17–47%). The median duration of response was 5.5 months for CBDCA and 6 months for CHIP; the median survival was 7.5 and 7.6 months, respectively. Both drugs were given in an outpatient setting and myelosuppression (thrombocytopenia) was the predominant toxicity. Analysis of all toxic events yielded additional interesting observations: the occurrence of moderate to severe platelet nadirs beyond cycle 1 was confined to CHIP, a higher incidence of gastrointestinal toxicity during treatment with CHIP, and five moderate to severe complaints of asthenia (recorded as neurologic events) during CHIP therapy versus only one during treatment with CBDCA. Because of its antitumor activity and its toxicologic advantage, a future role for CBDCA in the treatment of cervical cancer appears likely.
Similar content being viewed by others
References
Alberts DS, Mason-Liddil N (1989) The role of cisplatin in the management of advanced squamous cell cancer of the cervix. Semin Oncol 16 [Suppl 6]: 66–78
Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major F (1985) Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3: 1079–1085
Calvert AH, Harland SJ, Newell DR, Siddik RH, Jones AC, Mc Elwain TJ, Raju S, Wiltshaw E, Smith IE, Bahù JM, Peckam MJ, Harrap KR (1982) Early clinical studies withcis-diammine 1,1-cyclobutanedicarboxylate platinum(II). Cancer Chemother Pharmacol 9: 140–147
Calvert AH, Newell R, Gumbrell DA, O'Reilly S, Burrell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wittshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756
Canetta R, Bragman K, Smaldone L, Rozencweig M (1988) Carboplatin: current status and future prospects. Cancer Treat Rev 15 [Suppl B]: 17–32
Cohen JD, Robins HI (1987) Hyperthermia enhancement ofcis-diammine-1,1-cyclobutanedicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro. Cancer Res 47: 4335–4337
Lee ET (1980) Statistical methods for survival data analysis. Lifetime Learning Publications, Wadsworth, Belmont, California, pp 76–87, 129–130
Lira-Puerto V, Morales-Canfield F, Wernz J, Muggia FM (1984) Activity of mitolactol in cancer of the uterine cervix. Cancer Treat Rep 68 (4): 669–670
Lira-Puerto V, Piccart M, Wiernik P, Wernz J, Muggia F (1985) A comparison of US and Mexican experience with single drug therapy in advanced cervical cancer. Proc Am Soc Clin Oncol 4: 117
Lira-Puerto V, Silva A, Groshen S, Martinez R, Morris M, Morales-Canfield F, Tenorio F, Muggia F (1989) Carboplatin (CBDCA or CHIP: final report of the 3rd phase II NCI-PAHO study in advanced cervical cancer. Proc Am Soc Clin Oncol 8: 622
McGuire WP III, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, Teng NNH, Creasman WT (1989) A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix. A Gynecologic Oncology Group study. J Clin Oncol 7: 1462–1468
Monfardini S, Renard J, Pinedo HM, Cavalli F, Van Glabbeke M (1987) Clinical toxicity of the platinum analogs iproplatin (CHIP) and carboplatin (CBDCA). Invest New Drugs 5: (1.07) p 60
Muggia FM, Lira-Puerto V, Carugati A, Pavlovsky S (1985) Potential for platinum analogs in the treatment of cancer of the uterine cervix. Cancer Treat Rev 12 [Suppl A]: 93–99
O'Hara JA, Douple EB, Richmond RC (1985) Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells. In J Cancer Clin Oncol 23: 1399–1405
Oken MM, Creech KH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
Rose WC, Schurig JE (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12 [Suppl A]: 1–19
Zar JH (1984) Biostatistical analysis (2nd ed). Prentice Hall, Englewood Cliffs, New Jersey, pp 390–395
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lira-Puerto, V., Silva, A., Morris, M. et al. Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother. Pharmacol. 28, 391–396 (1991). https://doi.org/10.1007/BF00685695
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685695